Hailed by John Le Carre as an act of courage on the part of its author' and highly praised by leading medical journals on both sides of the Atlantic, Shah's expose of the unethical and lucrative exploits of the drugs trade in developing countries shines a much-needed spotlight on a growing trend. The multinational pharmaceutical industry has begun exporting its clinical research trials to the developing world, where ethical oversight is minimal and desperate patients abound. The world's poor frequently must either choose between experimentation or no drugs.'